MorphoSys AG has signed an initial two-year license agreement with Schering-Plough Corp. for the use of MorphoSys’s HuCAL GOLD technology in the R&D of human therapeutic antibodies. Under the terms of the agreement, MorphoSys will grant access to its proprietary antibody library to SP for use in its drug discovery programs at one research site. The contract provides SP with the option to develop HuCAL-derived therapeutic antibodies against as many as 10 disease-related targets. A...